The Anti-Neprilysin Market Poised to Grow at a Robust Pace Owing to Rising Prevalence of Cardiovascular Diseases
The anti-neprilysin market comprises drugs that inhibit neprilysin, a zinc metalloprotease enzyme involved in degrading natriuretic peptides and other vasoactive peptides. Neprilysin inhibitors are used for the treatment of heart failure as they help degrade peptides that are responsible for vasodilation and natriuresis. Increasing prevalence of cardiovascular diseases such as heart failure along with rapidly aging population are key factors augmenting the demand for neprilysin inhibitors.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the anti-neprilysin are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. Bioprojet is the frontrunner in development and commercialization of neprilysin inhibitors while Novartis and Theravance Biopharm are also actively involved in R&D of these drugs.
The market provides ample opportunities for players as anti-neprilysin drugs have potential applications in treatment of not just heart failure but also acute decompensated heart failure, acute myocardial infarction, and chronic kidney disease. More clinical studies are being conducted to evaluate efficacy of neprilysin inhibitors in these indications.
Global expansion remains a key focus for major players. While Bioprojet has commercialized sacubitril/valsartan in Europe and other major markets, Novartis AG is strengthening its presence worldwide through partnerships. Pharmaleads and Theravance Biopharm also aim to expand in clinical development and commercialization of neprilysin inhibitors globally over the forecast period.
Market Drivers
Rising geriatric population susceptible to cardiovascular ailments acts as a key driver for anti-neprilysin market. As per WHO, the number of people aged 65 years and above is projected to reach nearly 1.5 billion by 2050 from present 727 million. Since aging is a major risk factor for heart failure and related conditions, growing aged demography will significantly propel the demand.
Market Restrains
Stringent regulatory norms for approval of neprilysin inhibitors can restrain the market growth. However, ongoing research and new clinical data on efficacy of these drugs in various cardiac indications are expected to address regulatory challenges to a large extent over the coming years.
Segment Analysis
The Anti-Neprilysin market is segmented based on drug class, indication, route of administration, distribution channels, and geography. The neprilysin inhibitors segment dominates the market as drugs under this segment get preferred for the treatment of heart failure as neprilysin inhibitors help in improving renal function and heart health. Within this segment, sacubitril/valsartan combination drug is the largest revenue generating segment due to the proven benefits of this drug in reducing cardiovascular mortality and morbidity.
The heart failure indication segment accounts for the largest market share owing to the high usage of Anti-Neprilysin drugs for the treatment of heart failure. Oral administration is the preferred route of administration for Anti-Neprilysin drugs. Hospital pharmacy dominates the distribution channel segment as heart failure patients require medical supervision during the initial stages of drug therapy.
Global Analysis
Regionally, North America dominates the global Anti-Neprilysin market and is expected to continue its dominance during the forecast period. This is attributed to the rising burden of heart failure, growing geriatric population, favourable reimbursement policies, and presence of major pharma companies in the region. Europe holds the second largest market share owing to the increasing focus of pharmaceutical companies on R&D activities for drug development. The Asia Pacific region is projected to witness the highest growth rate globally during the forecast period due to the improving healthcare infrastructure, increasing healthcare expenditure, growing awareness about cardiovascular disorders, and expanding target patient pool.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian